Search Results - Jensen Yeung, MD, FRCPC

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study by Yuliya Lytvyn, PhD, Hiba Zaaroura, MD, Asfandyar Mufti, MD, Shaikhah AlAbdulrazzaq, MD, Jensen Yeung, MD, FRCPC

Connect to this object online.

Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series by Michelle Phung, BMSc, Jorge R. Georgakopoulos, BSc, Arvin Ighani, BMSc, Lyne Giroux, MD, FRCPC, Jensen Yeung, MD, FRCPC

Connect to this object online.

Treatment outcomes in patients with papuloerythroderma of Ofuji: A systematic review by Asfandyar Mufti, MD, Yuliya Lytvyn, PhD, Abrahim Abduelmula, BScN, Patrick Kim, BHSc, Muskaan Sachdeva, BHSc, Jensen Yeung, MD, FRCPC

Connect to this object online.

Treatment outcomes of biologics and small molecules for chronic hand eczema: An evidence-based systematic review by Siddhartha Sood, HBSc, Edgar Akuffo-Addo, MHA, Jorge R. Georgakopoulos, MD, Asfandyar Mufti, MD, FRCPC, Khalad Maliyar, MD, Jensen Yeung, MD, FRCPC

Connect to this object online.

A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy by Muskaan Sachdeva, BHSc, Asfandyar Mufti, MD, Nadia Kashetsky, MSc, Jorge R. Georgakopoulos, MD, Sheida Naderi-Azad, BSc, Jennifer Salsberg, MD, FRCPC, Jensen Yeung, MD, FRCPC

Connect to this object online.

Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literatureCapsule Summary by Asfandyar Mufti, MD, Sara Mirali, PhD, Abrahim Abduelmula, BScN, Katherine Ann McDonald, MD, Shaikhah Alabdulrazzaq, BMBCh, Muskaan Sachdeva, BHSc, Jensen Yeung, MD, FRCPC

Connect to this object online.

Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study by Jorge R. Georgakopoulos, MD, Tina Felfeli, MD, Aaron M. Drucker, MD, ScM, FRCPC, Christine E. Jo, BSc, Vincent Piguet, MD, PhD, FRCP, Jensen Yeung, MD, FRCPC

Connect to this object online.

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study by Yuliya Lytvyn, PhD, Asfandyar Mufti, MD, Hiba Zaaroura, MD, Muskaan Sachdeva, BHSc, Justin D. Lu, MSc, Brian D. Rankin, PhD, Vimal H. Prajapati, MD, Ronald Vender, MD, Jensen Yeung, MD, FRCPC

Connect to this object online.